Unicycive Therapeutics (UNCY) Cash from Investing Activities (2022 - 2026)
Unicycive Therapeutics posted quarterly Cash from Investing Activities of -$5.2 million for Q1 2026, down 32118.75% year-on-year from N/an in Q1 2025, and up 57.29% on a QoQ basis from -$12.1 million in Q4 2025.
Unicycive Therapeutics (UNCY) has 4 years of Cash from Investing Activities data on file, last reported at -$5.2 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 32118.75% year-over-year to -$5.2 million; the trailing twelve-month figure through Mar 2026 stood at -$17.2 million (down 20917.07% YoY), and the FY2025 full-year result was -$12.1 million, down 16698.61% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$5.2 million, up from -$12.1 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$2000.0 in Q1 2022 and bottomed at -$12.1 million in Q4 2025.
- The 4-year median for Cash from Investing Activities is -$18000.0 (2024), against an average of -$1.7 million.
- Peak annual rise in Cash from Investing Activities reached 91.67% in 2025, while the deepest fall reached 54768.18% in 2025.
- A 4-year view of Cash from Investing Activities shows it stood at -$2000.0 in 2022, then tumbled by 1000.0% to -$22000.0 in 2024, then tumbled by 54768.18% to -$12.1 million in 2025, then soared by 57.29% to -$5.2 million in 2026.
- The last three Cash from Investing Activities figures came in at -$5.2 million (Q1 2026), -$12.1 million (Q4 2025), and -$2000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | -5.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.16 Mn |
| Mar 31, 2026 | -5.16 Mn |
| Dec 31, 2025 | -12.07 Mn |
| Dec 31, 2025 | -12.07 Mn |
| Sep 30, 2025 | -2,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Mar 31, 2025 | -16,000.00 |
| Mar 31, 2025 | -16,000.00 |
| Dec 31, 2024 | -22,000.00 |
| Dec 31, 2024 | -22,000.00 |
| Sep 30, 2024 | -24,000.00 |
| Sep 30, 2024 | -24,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Mar 31, 2024 | -6,000.00 |
| Mar 31, 2024 | -6,000.00 |
| Mar 31, 2022 | -2,000.00 |
| Mar 31, 2022 | -2,000.00 |